This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Victoza
  • /
  • The Effect of Liraglutide on Bone Turnover, Bone M...
Clinical trial

The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function (LIRABONE)

Read time: 1 mins
Last updated:31st Jul 2015

The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function. Type 2 diabetes may cause multiple complications, and it is well known that patients with type 2 diabetes have a higher risk of fractures. If Liraglutide can be demonstrated to have a positive effect on bone, this may be one among other factors to consider before the decision about specific treatment of type 2 diabetes is made for the individual patient.


Study Type: Interventional

Study Design: Allocation: Randomized

Intervention Model: Parallel Assignment

Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Primary Purpose: Treatment

Official Title: The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

Estimated Enrollment: 60

Study Start Date: August 2015

Estimated Study Completion Date: August 2016

Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)


Experimental: Liraglutide

Placebo Comparator: Placebo

Category Value
Study start date 2015-08-01

View full details